Lynk Pharmaceuticals advances zemprocitinib towards China approval after positive Phase 3 rheumatoid arthritis results
Zemprocitinib enters China's NMPA review after positive Phase 3 rheumatoid arthritis data, with long-term safety and commercial access in focus.